Lisdexamfetamine dimesylate

<table>
<thead>
<tr>
<th>Chem. Name</th>
<th>(25)-2,6-diamino-N-[(25)-1-phenylpropan-2-yl]hexanamide</th>
</tr>
</thead>
<tbody>
<tr>
<td>Formula</td>
<td>C_{15}H_{25}N_{3}O</td>
</tr>
<tr>
<td>MW</td>
<td>263.378 g/mol</td>
</tr>
<tr>
<td>CAS</td>
<td>608137-32-2</td>
</tr>
</tbody>
</table>

**Therapeutic area**
- Attention deficit hyperactivity disorder (ADHD)
- Controlled substance in some countries

**Quality**
- In-house standards

**Regulatory status**
- Canadian ASMF
- The facility’s Quality System is based on the requirements stated in Eudralex vol. 4, part II Guidance for Active Pharmaceutical Ingredients
- Facility inspected by the Danish Medicines Agency (DKMA)

**Packing**
- Airtight laminated aluminium bags

**Production site**
- Chr. Olesen Synthesis A/S, Kanalholmen 8-12, DK 2650 Hvidovre, Denmark

Samples for R&D use in the United States are available as permitted under 35 USC § 271 (e)(1). Product currently under patent protection could be available only for R&D purposes, if this is allowed by local laws. Products covered by valid patents in any country are not offered or supplied to these countries for commercial use. However, the final responsibility lies exclusively on the buyer.